Skip to main content
Christina Ohnsman, MD, Ophthalmology, Reading, PA

ChristinaMOhnsmanMD

Ophthalmology Reading, PA

Pediatric & Strabismus

President, CMO Medical Communications, LLC

Dr. Ohnsman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Ohnsman's full profile

Already have an account?

  • Office

    115 Grandview Blvd
    Reading, PA 19609
    Phone+1 610-914-2718

Summary

  • After over 20 years as a practicing pediatric ophthalmologist, I am now a medical writer and consultant with expertise in ophthalmology, gene therapy, and rare and orphan diseases. As president of CMO Medical Communications, LLC, I remain dedicated to my consistent, passionate focus on improving patients’ lives.

Education & Training

  • Children's Hospital Medical Center of Akron/NEOMED
    Children's Hospital Medical Center of Akron/NEOMEDFellowship, Pediatric Ophthalmology, 1993 - 1994
  • University of Cincinnati Medical Center/College of Medicine
    University of Cincinnati Medical Center/College of MedicineResidency, Ophthalmology, 1990 - 1993
  • Atlantic Health System/Morristown Medical Center
    Atlantic Health System/Morristown Medical CenterInternship, Internal Medicine, 1989 - 1990
  • Rutgers New Jersey Medical School
    Rutgers New Jersey Medical SchoolClass of 1989

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1994 - 2024
  • OH State Medical License
    OH State Medical License 1990 - 1994
  • American Board of Ophthalmology Ophthalmology

Publications & Presentations

PubMed

Journal Articles

  • Brave New World: Gene Therapy for Inherited Retinal Disease  
    Leroy BP, Pennesi ME, Ohnsman, CM, EyeNet, 7/1/2018

Books/Book Chapters

Abstracts/Posters

  • RPE65 Mutation Subtype Effect on Baseline Visual Function and Treatment Response in Phase 3 Voretigene Neparvovec Trial
    Mahajan VB, Bennett J, Maguire A, Haller J, Leroy BP, Sohn EH, Drack A, Ohnsman CM, Ciulla T, Chung D, High KA, Annual Meeting of the American Academy of Ophthalmology, Chicago, IL, 10/27/2018

Other

Authored Content

  • Rare Diseases Aren't That RareFebruary 2019
  • Rare Diseases Aren't That RareFebruary 2019

Professional Memberships